Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
Alectinib is a selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor as standard therapy for ALK-rearranged non-small cell lung cancer (NSCLC). Hemolytic anemia is considered as a rare but significant adverse event with alectinib. Here, we report a case of a 73-year-old female with lu...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2023-01, Vol.16, p.65-69 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 69 |
|---|---|
| container_issue | |
| container_start_page | 65 |
| container_title | OncoTargets and therapy |
| container_volume | 16 |
| creator | Misawa, Kazuhito Nakamichi, Shinji Iida, Hiroki Nagano, Atsuhiro Mikami, Erika Tozuka, Takehiro Matsumoto, Masaru Miyanaga, Akihiko Noro, Rintaro Kubota, Kaoru Yamaguchi, Hiroki Seike, Masahiro |
| description | Alectinib is a selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor as standard therapy for ALK-rearranged non-small cell lung cancer (NSCLC). Hemolytic anemia is considered as a rare but significant adverse event with alectinib. Here, we report a case of a 73-year-old female with lung adenocarcinoma, harbouring an ALK fusion gene, who received alectinib as second-line therapy and developed gradually progressive grade 4 (6.4 g/dL) drug-induced hemolytic anemia (DIHA) after complete response. We discontinued alectinib and performed a blood transfusion for the severe anemia. The anemia improved with no recurrence of lung adenocarcinoma over 10 months. Regular hematologic monitoring and the possibility of DIHA should be considered in case of progressive hemolytic anemia during alectinib treatment. |
| doi_str_mv | 10.2147/OTT.S398375 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9884059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A737699829</galeid><sourcerecordid>A737699829</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-7e9a51d07b4c587aafd902f7852dde23fb513328c94c78e69e5e63d8a238a5213</originalsourceid><addsrcrecordid>eNptkt2LEzEUxQdR3HX1yXcJCL7I1MnHTBIfhKGou1jcxdbnkGbutFlmkppkKvvfm2Xr2oIEkkPyu4ebyymK17iaEcz4h-vVarakUlBePynOMeaibCStnh7ps-JFjLdV1TSCsOfFGW04zoqdF6EdwCTr7Lq8ct1koENL2EMAdAmjH-6SNah1MFqNrEMa3ehkwSX026YtahffyhsfbbJ7QN-9K5ejHgY0h7wtJrdBc-0MhI-ozSoC-gE7H9LL4lmvhwivDudF8fPL59X8slxcf72at4vSMM5SyUHqGncVXzNTC65138mK9FzUpOuA0H5dY0qJMJIZLqCRUENDO6EJFbommF4Unx58d9N6hM7ktoMe1C7YUYc75bVVpy_ObtXG75UUglW1zAZvDwbB_5ogJnXrp-Byz4pwzhklNWH_qI0eQFnX-2xmRhuNajnljZSC3HvN_kPl1eXZGu-gt_n-pODdUcEW9JC20Q9Tst7FU_D9A2iCjzFA__hDXKn7gKgcEHUISKbfHA_lkf2bCPoHnlazzg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2777432524</pqid></control><display><type>article</type><title>Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Misawa, Kazuhito ; Nakamichi, Shinji ; Iida, Hiroki ; Nagano, Atsuhiro ; Mikami, Erika ; Tozuka, Takehiro ; Matsumoto, Masaru ; Miyanaga, Akihiko ; Noro, Rintaro ; Kubota, Kaoru ; Yamaguchi, Hiroki ; Seike, Masahiro</creator><creatorcontrib>Misawa, Kazuhito ; Nakamichi, Shinji ; Iida, Hiroki ; Nagano, Atsuhiro ; Mikami, Erika ; Tozuka, Takehiro ; Matsumoto, Masaru ; Miyanaga, Akihiko ; Noro, Rintaro ; Kubota, Kaoru ; Yamaguchi, Hiroki ; Seike, Masahiro</creatorcontrib><description>Alectinib is a selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor as standard therapy for ALK-rearranged non-small cell lung cancer (NSCLC). Hemolytic anemia is considered as a rare but significant adverse event with alectinib. Here, we report a case of a 73-year-old female with lung adenocarcinoma, harbouring an ALK fusion gene, who received alectinib as second-line therapy and developed gradually progressive grade 4 (6.4 g/dL) drug-induced hemolytic anemia (DIHA) after complete response. We discontinued alectinib and performed a blood transfusion for the severe anemia. The anemia improved with no recurrence of lung adenocarcinoma over 10 months. Regular hematologic monitoring and the possibility of DIHA should be considered in case of progressive hemolytic anemia during alectinib treatment.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S398375</identifier><identifier>PMID: 36718244</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Adenocarcinoma ; Anemia ; Antimitotic agents ; Antineoplastic agents ; Blood transfusion ; Blood transfusions ; Cancer therapies ; Care and treatment ; Case Report ; Case reports ; Drug dosages ; Fusion protein ; Hemoglobin ; Hemolytic anemia ; Laboratories ; Lung cancer ; Lung cancer, Non-small cell ; Lung cancer, Small cell ; Lymphatic system ; Lymphomas ; Metastasis ; Morphology ; Non-small cell lung carcinoma ; Patients ; Protein-tyrosine kinase ; Small cell lung carcinoma ; Tomography</subject><ispartof>OncoTargets and therapy, 2023-01, Vol.16, p.65-69</ispartof><rights>2023 Misawa et al.</rights><rights>COPYRIGHT 2023 Dove Medical Press Limited</rights><rights>2023. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Misawa et al. 2023 Misawa et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-7e9a51d07b4c587aafd902f7852dde23fb513328c94c78e69e5e63d8a238a5213</citedby><cites>FETCH-LOGICAL-c474t-7e9a51d07b4c587aafd902f7852dde23fb513328c94c78e69e5e63d8a238a5213</cites><orcidid>0000-0002-4948-2245 ; 0000-0002-3774-8915 ; 0000-0003-2026-9181</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884059/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884059/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3848,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36718244$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Misawa, Kazuhito</creatorcontrib><creatorcontrib>Nakamichi, Shinji</creatorcontrib><creatorcontrib>Iida, Hiroki</creatorcontrib><creatorcontrib>Nagano, Atsuhiro</creatorcontrib><creatorcontrib>Mikami, Erika</creatorcontrib><creatorcontrib>Tozuka, Takehiro</creatorcontrib><creatorcontrib>Matsumoto, Masaru</creatorcontrib><creatorcontrib>Miyanaga, Akihiko</creatorcontrib><creatorcontrib>Noro, Rintaro</creatorcontrib><creatorcontrib>Kubota, Kaoru</creatorcontrib><creatorcontrib>Yamaguchi, Hiroki</creatorcontrib><creatorcontrib>Seike, Masahiro</creatorcontrib><title>Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Alectinib is a selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor as standard therapy for ALK-rearranged non-small cell lung cancer (NSCLC). Hemolytic anemia is considered as a rare but significant adverse event with alectinib. Here, we report a case of a 73-year-old female with lung adenocarcinoma, harbouring an ALK fusion gene, who received alectinib as second-line therapy and developed gradually progressive grade 4 (6.4 g/dL) drug-induced hemolytic anemia (DIHA) after complete response. We discontinued alectinib and performed a blood transfusion for the severe anemia. The anemia improved with no recurrence of lung adenocarcinoma over 10 months. Regular hematologic monitoring and the possibility of DIHA should be considered in case of progressive hemolytic anemia during alectinib treatment.</description><subject>Adenocarcinoma</subject><subject>Anemia</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Blood transfusion</subject><subject>Blood transfusions</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Drug dosages</subject><subject>Fusion protein</subject><subject>Hemoglobin</subject><subject>Hemolytic anemia</subject><subject>Laboratories</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung cancer, Small cell</subject><subject>Lymphatic system</subject><subject>Lymphomas</subject><subject>Metastasis</subject><subject>Morphology</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Protein-tyrosine kinase</subject><subject>Small cell lung carcinoma</subject><subject>Tomography</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkt2LEzEUxQdR3HX1yXcJCL7I1MnHTBIfhKGou1jcxdbnkGbutFlmkppkKvvfm2Xr2oIEkkPyu4ebyymK17iaEcz4h-vVarakUlBePynOMeaibCStnh7ps-JFjLdV1TSCsOfFGW04zoqdF6EdwCTr7Lq8ct1koENL2EMAdAmjH-6SNah1MFqNrEMa3ehkwSX026YtahffyhsfbbJ7QN-9K5ejHgY0h7wtJrdBc-0MhI-ozSoC-gE7H9LL4lmvhwivDudF8fPL59X8slxcf72at4vSMM5SyUHqGncVXzNTC65138mK9FzUpOuA0H5dY0qJMJIZLqCRUENDO6EJFbommF4Unx58d9N6hM7ktoMe1C7YUYc75bVVpy_ObtXG75UUglW1zAZvDwbB_5ogJnXrp-Byz4pwzhklNWH_qI0eQFnX-2xmRhuNajnljZSC3HvN_kPl1eXZGu-gt_n-pODdUcEW9JC20Q9Tst7FU_D9A2iCjzFA__hDXKn7gKgcEHUISKbfHA_lkf2bCPoHnlazzg</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Misawa, Kazuhito</creator><creator>Nakamichi, Shinji</creator><creator>Iida, Hiroki</creator><creator>Nagano, Atsuhiro</creator><creator>Mikami, Erika</creator><creator>Tozuka, Takehiro</creator><creator>Matsumoto, Masaru</creator><creator>Miyanaga, Akihiko</creator><creator>Noro, Rintaro</creator><creator>Kubota, Kaoru</creator><creator>Yamaguchi, Hiroki</creator><creator>Seike, Masahiro</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4948-2245</orcidid><orcidid>https://orcid.org/0000-0002-3774-8915</orcidid><orcidid>https://orcid.org/0000-0003-2026-9181</orcidid></search><sort><creationdate>20230101</creationdate><title>Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report</title><author>Misawa, Kazuhito ; Nakamichi, Shinji ; Iida, Hiroki ; Nagano, Atsuhiro ; Mikami, Erika ; Tozuka, Takehiro ; Matsumoto, Masaru ; Miyanaga, Akihiko ; Noro, Rintaro ; Kubota, Kaoru ; Yamaguchi, Hiroki ; Seike, Masahiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-7e9a51d07b4c587aafd902f7852dde23fb513328c94c78e69e5e63d8a238a5213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma</topic><topic>Anemia</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Blood transfusion</topic><topic>Blood transfusions</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Drug dosages</topic><topic>Fusion protein</topic><topic>Hemoglobin</topic><topic>Hemolytic anemia</topic><topic>Laboratories</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung cancer, Small cell</topic><topic>Lymphatic system</topic><topic>Lymphomas</topic><topic>Metastasis</topic><topic>Morphology</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Protein-tyrosine kinase</topic><topic>Small cell lung carcinoma</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Misawa, Kazuhito</creatorcontrib><creatorcontrib>Nakamichi, Shinji</creatorcontrib><creatorcontrib>Iida, Hiroki</creatorcontrib><creatorcontrib>Nagano, Atsuhiro</creatorcontrib><creatorcontrib>Mikami, Erika</creatorcontrib><creatorcontrib>Tozuka, Takehiro</creatorcontrib><creatorcontrib>Matsumoto, Masaru</creatorcontrib><creatorcontrib>Miyanaga, Akihiko</creatorcontrib><creatorcontrib>Noro, Rintaro</creatorcontrib><creatorcontrib>Kubota, Kaoru</creatorcontrib><creatorcontrib>Yamaguchi, Hiroki</creatorcontrib><creatorcontrib>Seike, Masahiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Misawa, Kazuhito</au><au>Nakamichi, Shinji</au><au>Iida, Hiroki</au><au>Nagano, Atsuhiro</au><au>Mikami, Erika</au><au>Tozuka, Takehiro</au><au>Matsumoto, Masaru</au><au>Miyanaga, Akihiko</au><au>Noro, Rintaro</au><au>Kubota, Kaoru</au><au>Yamaguchi, Hiroki</au><au>Seike, Masahiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>16</volume><spage>65</spage><epage>69</epage><pages>65-69</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Alectinib is a selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor as standard therapy for ALK-rearranged non-small cell lung cancer (NSCLC). Hemolytic anemia is considered as a rare but significant adverse event with alectinib. Here, we report a case of a 73-year-old female with lung adenocarcinoma, harbouring an ALK fusion gene, who received alectinib as second-line therapy and developed gradually progressive grade 4 (6.4 g/dL) drug-induced hemolytic anemia (DIHA) after complete response. We discontinued alectinib and performed a blood transfusion for the severe anemia. The anemia improved with no recurrence of lung adenocarcinoma over 10 months. Regular hematologic monitoring and the possibility of DIHA should be considered in case of progressive hemolytic anemia during alectinib treatment.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>36718244</pmid><doi>10.2147/OTT.S398375</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-4948-2245</orcidid><orcidid>https://orcid.org/0000-0002-3774-8915</orcidid><orcidid>https://orcid.org/0000-0003-2026-9181</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2023-01, Vol.16, p.65-69 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9884059 |
| source | Taylor & Francis Open Access; DOVE Medical Press Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adenocarcinoma Anemia Antimitotic agents Antineoplastic agents Blood transfusion Blood transfusions Cancer therapies Care and treatment Case Report Case reports Drug dosages Fusion protein Hemoglobin Hemolytic anemia Laboratories Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell Lymphatic system Lymphomas Metastasis Morphology Non-small cell lung carcinoma Patients Protein-tyrosine kinase Small cell lung carcinoma Tomography |
| title | Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A50%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alectinib-Induced%20Severe%20Hemolytic%20Anemia%20in%20a%20Patient%20with%20ALK-Positive%20Non-Small%20Cell%20Lung%20Cancer:%20A%20Case%20Report&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Misawa,%20Kazuhito&rft.date=2023-01-01&rft.volume=16&rft.spage=65&rft.epage=69&rft.pages=65-69&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S398375&rft_dat=%3Cgale_pubme%3EA737699829%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2777432524&rft_id=info:pmid/36718244&rft_galeid=A737699829&rfr_iscdi=true |